Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Phase 1 in advanced solid tumors
NCT02827968Phase 1Completed
- Sponsor
- 3D Medicines Inc.
- Start
- Jan 2017
- Primary completion
- Aug 2020
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of envafolimab in solid tumor, sponsored by 3D Medicines Inc. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Adverse Events up to 3 months. Started Jan 2017; status: completed.
02
Drugs
envafolimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02827968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827968.